TVTX Travere Therapeutics Inc

I've been overly harsh on myself for the ones I sold early $TVTX $URGN $IOVA But binary blow ups of late in bioland are a reminder that a bird in the hand... is truly a valuable thing

$TVTX Advice to new CEO: SG&A and R&D costs are simply too high. Pare down the R&D agenda substantially, shrink the back office functions, and invest in more sales & support teams. Producing $700 million in revenue, should yield a very profitable print—instead, it’s all being consumed in the currently bloated organization and agenda. Streamline, singular focus, dramatically scale Filspari, and have the Board announce ‘exploring strategic alternatives’. A bidding war would get valuation close to $100 / share. $NVS has a 3.3% div yield, if acquired in shares, ride it out for years. Let’s get this done.

$TVTX Three of four threaputic stocks on IBD are in the red today. Seems to be a sector issue. $TVTX is getting a 2X whipping. Not seeing an news that justifys this other than the CEO change announced several days ago.

$TVTX Good to see a move back upwards, but I was expecting more like $75 after the FSGS patent extension news.

$TVTX I don’t reconcile the behavior in trading, after FSGS patent extension to 2037. An additional 5 years (from 2032 to 2037), at a peak FSGS revenue of say $700 million, is an additional $3.5 billion of revenue stream for TVTX. That should be reflected in a $8 to $12 gap upwards in price today. it would certainly contribute to an increased acquisition price of TVTX. Perhaps for $SNY I expect $95 to $105 buyout in H1 next year. Exactly inline with Sanofi criteria recently laid out by CEO.

$TVTX any clues on this flogging today? Institutional profit taking or Fed rates at 2pm EST?